Sartorius Stedim Biotech : Q4 prelims due 26 Jan – Incorporating higher destocking effect
>Q4 expected to have a similar momentum compared to Q3 - Sartorius Stedim' preliminary Q4 revenues of € 747m (-16.1% y-o-y) should be impacted by destocking in the biopharma and biotech industry. It is our understanding that order pattern of customers are still volatile and order sizes have become smaller. We expect the positive trend from the third quarter (order intake up 14% sequentially q-o-q) will continue with 17% sequential growth to a level of € 721m. It is ou...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.